AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Reported by Yahoo Finance · Published 14 Sep 2026, 11:00 PM MYT (1 d ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

How rising bond yields impact American consumers 9 min ago Malaysia talks to rival airlines as it monitors AirAsia’s financial health 18 min ago XRP sinks 10% as the Clarity Act fails and bitcoin slides toward $76,000 30 min ago Apollo Global Management provides $585 million financing to office provider TEC 1 hr ago BOJ set to raise interest rates to 31-year high as inflation risks loom 1 hr ago Boeing, Korean Air finalize order for 103 aircraft 1 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Summary

More in Markets

These 4 stocks could benefit most from a $3.2 trillion semiconductor opportunity

Inflation killed the penny. Now it’s coming for your dollar.

2 charts showing how oil is becoming the global market’s biggest wild card

Why a Federal Reserve rate hike could be a ‘rare win’ for your retirement money

Top Senate Republican floats a diesel export ban as prices soar. It might not work.

Oracle’s stock falls for the fifth day in a row — missing out on the AI bounce